

**Amendments to the Claims:**

Please amend the claims and add new claims, as follows.

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

**Claims 1-26.** (Previously Canceled)

**Claim 27.** (Currently Amended) A process for the production of a scopolamine free base containing transdermal system substantially free of crystals of scopolamine free base, comprising annealing scopolamine free base containing layers of said transdermal system at a temperature above the melting point of the crystals for a period of time sufficient to melt ~~the scopolamine free base anhydrous~~ crystals, wherein the annealing process is performed ~~within about 24 hours of after~~ casting a scopolamine free base containing formulation onto a web or after forming a laminate with a scopolamine free base containing formulation for use in constructing said transdermal system substantially free of scopolamine free base anhydrous crystals.

**Claim 28.** (Previously Presented) The process of claim 27, wherein said transdermal system is further packaged and further heat treated at a temperature of at least 67° C to about 90° C for a period of about 4 hours to about 24 hours.

**Claim 29.** (Currently Amended) The process of claim ~~17~~27, wherein said annealing takes place at about 75° C to about 90° C.

**Claim 30.** (Previously Presented) The process of claim 27, wherein said annealing takes place over a period of about 2 – 10 minutes.

**Claim 31.** (Previously Presented) The process of claim 27, wherein a drug reservoir layer containing scopolamine free base and a contract adhesive layer containing scopolamine free base are each separately annealed, then contacted and further annealed prior to packaging.

**Claim 32.** (Currently Amended) A method for manufacturing delivery devices for the transdermal administration of scopolamine comprising, in combination:

- a. forming a laminate, at least one lamina of which comprises a dispersion of said scopolamine in a non-aqueous matrix;
  - b. cutting subunits forming said delivery devices from said laminate;
  - c. packaging said delivery devices in sealed containers;
  - d. heating said delivery devices in said containers to a temperature above the melting point of anhydrous crystalline scopolamine ~~hydrate~~ and maintaining said delivery devices at such temperature for a time sufficient to prevent the formation or eliminate the presence of anhydrous crystals of scopolamine ~~hydrate~~ for a substantial period of time after cooling of the subunits to ambient temperatures; and
  - e. cooling the delivery devices to ambient temperatures;
- wherein the improvement comprising heating at least each scopolamine containing layer to a temperature exceeding the melting point of scopolamine anhydrous crystal for a period of time sufficient to melt the crystals, ~~which improvement~~ the heating step is being conducted prior to ~~but within about 24 hours~~, or during the process, ~~or~~ of laminating and/or sealing the scopolamine containing layer.

**Claim 33.** (New) A process for the production of a scopolamine free base containing transdermal system substantially free of anhydrous crystals of scopolamine free base, comprising annealing scopolamine free base containing layers of said transdermal system at a temperature above the melting point of the anhydrous crystals for a period of time sufficient to melt the crystals, wherein the annealing process is performed within a period after casting a scopolamine free base containing formulation onto a web for use in constructing said transdermal system so as to result in a transdermal system substantially free of anhydrous scopolamine crystals, wherein said annealing takes place at about 75° C to about 90° C.

**Claim 34.** (New) The process of claim 27, wherein the heating and annealing process is done immediately after casting a scopolamine free base containing formulation onto a web or immediately after forming a laminate with a scopolamine free base containing formulation.

**Claim 35.** (New) The process of claim 27, further comprising annealing the transdermal system at a temperature above the melting point of scopolamine after packaging in pouch.

**Claim 36.** (New) The process of claim 27, further comprising annealing a laminate that includes a scopolamine free base containing layer laminated to a nonporous non-scopolamine-containing layer.

**Claim 37.** (New) The process of claim 36, further comprising removing the nonporous non-scopolamine-containing layer before packaging the transdermal system in pouch.

**Claim 38.** (New) The process of claim 27, comprising two heating and annealing steps, one heating step being immediately after casting the scopolamine free base containing formulation onto a web.